Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kong Website

Heidi H. Kong, M.D., M.H.Sc.

Selected Publications

1)  Findley K, Oh J, Yang J, Conlan S, Deming C, Meyer JA, Schoenfeld D, Nomicos E, Park M, Kong HH, Segre JA.
Topographic diversity of fungal and bacterial communities in human skin.
Nature. 498: 367-70, 2013.
[Journal]
2)  Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C, Quinones M, Koo L, Conlan S, Spencer S, Hall JA, Dzutsev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, Belkaid Y.
Compartmentalized control of skin immunity by resident commensals.
Science. 337: 1115-9, 2012.
[Journal]
3)  Methe B, Nelson K, Pop M, et al .
A framework for human microbiome research.
Nature. 486: 215-21, 2012.
[Journal]
4)  Larson D, Cooper PJ, Hübner MP, Reyes J, Vaca M, Chico M, Kong HH, Mitre E.
Helminth infection is associated with decreased basophil responsiveness in humans.
J Allergy Clin Immunol. 130: 270-2, 2012.
[Journal]
5)  Oh J, Conlan S, Polley EC, Segre JA, Kong HH.
Shifts in human skin and nares microbiota of healthy children and adults.
Genome Med. 4: 77, 2012.
[Journal]
6)  Kong HH, Segre JA.
Skin microbiome: looking back to move forward.
J. Invest. Dermatol. 132: 933-9, 2012.
[Journal]
7)  Conlan S, Kong HH, Segre JA.
Species-level analysis of DNA sequence data from the NIH Human Microbiome Project.
PLoS ONE. 7: e47075, 2012.
[Journal]
8)  Conlan S, Mijares LA, Becker J, Blakesley RW, Bouffard GG, Brooks S, Coleman H, Gupta J, Gurson N, Park M, Schmidt B, Thomas PJ, Otto M, Kong HH, Murray PR, Segre JA.
Staphylococcus epidermidis pan-genome sequence analysis reveals diversity of skin commensal and hospital infection-associated isolates.
Genome Biol. 13: R64, 2012.
[Journal]
9)  Huttenhower C, Gevers D, Knight R, et al .
Structure, function and diversity of the healthy human microbiome.
Nature. 486: 207-14, 2012.
[Journal]
10)  Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA.
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis.
Genome Res. 22: 850-9, 2012.
[Journal]
11)  Kong HH.
Skin microbiome: genomics-based insights into the diversity and role of skin microbes.
Trends Mol Med. 17: 320-8, 2011.
[Journal]
12)  Brooks S, Linehan WM, Srinivasan R, Kong HH.
Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Arch Dermatol. 147: 364-5, 2011.
[Journal]
13)  Kelly JJ, Freeman AF, Wang H, Cowen EW, Kong HH.
An Amish boy with recurrent ulcerations of the lower extremities, telangiectases of the hands, and chronic lung disease.
J. Am. Acad. Dermatol. 62: 1031-4, 2010.
[Journal]
14)  Kong HH, Segre JA.
Bridging the translational research gap: a successful partnership involving a physician and a basic scientist.
J. Invest. Dermatol. 130: 1478-80, 2010.
[Journal]
15)  Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH.
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Pharmacotherapy. 30: 52-6, 2010.
[Journal]
16)  Kong HH, Turner ML.
Array of cutaneous adverse effects associated with sorafenib.
J. Am. Acad. Dermatol. 61: 360-1, 2009.
[Journal]
17)  Kong HH, Fine HA, Stern JB, Turner ML.
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Arch Dermatol. 145: 923-5, 2009.
[Journal]
18)  Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH.
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clin. Cancer Res. 15: 1411-6, 2009.
[Journal]
19)  Azad NS, Aragon-Ching JB, Kong HH.
Letter to the Editor.
Clin Cancer Res. 15: 7749, 2009.
[Journal]
20)  Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA.
Topographical and temporal diversity of the human skin microbiome.
Science. 324: 1190-2, 2009.
[Journal]
21)  Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW, Wolfsberg TG, Turner ML, Segre JA.
A diversity profile of the human skin microbiota.
Genome Res. 18: 1043-50, 2008.
[Journal]
22)  Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP.
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Oncologist. 13: 1001-11, 2008.
[Journal]
23)  Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.
Sorafenib-induced eruptive melanocytic lesions.
Arch Dermatol. 144: 820-2, 2008.
[Journal]
24)  Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML.
Keratoacanthomas associated with sorafenib therapy.
J. Am. Acad. Dermatol. 56: 171-2, 2007.
[Journal]
25)  Kong HH, Myers SA.
Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Dermatol Ther. 18: 58-66, 2005.
[Journal]
26)  Kong HH, Prose NS, Ware RE, Hall RP.
Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Pediatr Dermatol. 22: 461-4, 2005.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/17/2013.